PAP
APGE icon

Persistent Asset Partners’s Apogee Therapeutics APGE Stock Holding History

Persistent Asset Partners’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,445
Closed -$178K – 335
2025
Q4 		$185K Sell
2,445
-12,374
-84% -$779K 0.08% 220
2025
Q3 		$589K Buy
14,819
+12,394
+511% +$473K 0.4% 77
2025
Q2 		$105K Sell
2,425
-6,753
-74% -$257K 0.08% 126
2025
Q1 		$343K Sell
9,178
-8,762
-49% -$339K 0.29% 72
2024
Q4 		$742K Buy
+17,940
New +$915K 0.62% 46

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Persistent Asset Partners's APGE Position: Q1 2026 in Review

Persistent Asset Partners sold out of Apogee Therapeutics (APGE) in Q1 2026, closing a stake of 2,445 shares — an estimated $178K sold.

Persistent Asset Partners first reported a position in APGE in Q4 2024 and held it in 5 quarters. The position peaked at $742K in Q4 2024. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Persistent Asset Partners reported no remaining Apogee Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 2,445 Apogee Therapeutics shares in Q1 2026, an estimated $178K.
  • Persistent Asset Partners first reported a position in Apogee Therapeutics in Q4 2024 and held it in 5 quarters.
  • Persistent Asset Partners's Apogee Therapeutics position peaked at $742K in Q4 2024.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.